HR9418Referred to Committee

To amend title XVIII of the Social Security Act to provide a review process for adverse national coverage determinations with respect to drug coverage under the Medicare program.

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2026-06-24
Introduced
1
Cosponsors
HR
Type

Sponsor

Nanette Diaz Barragán
Nanette Diaz Barragán
Democrat · CA · Representative
Votes with party: 98.6% (568 recorded votes)

Full profile: /officials/B001300

Source: Congress.gov · FEC

Cosponsors (1)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

2026-06-24

Source: Congress.gov

Committee Activity

Currently in

Plain-English Summary

Medicare patients and drug manufacturers would gain a formal review process to challenge decisions by Medicare that deny coverage for certain medications nationwide. Currently, when Medicare decides not to cover a drug, there is limited opportunity to appeal that decision; this change would create a structured way to request reconsideration and present new evidence. The review process would apply specifically to these national coverage denials, giving patients and companies a clearer path to contest decisions they believe are unfair.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Full bill text is not yet cached locally.